Immuron

{{Short description|Biotechnology company based in Melbourne, Australia}}

{{Notability|1=Companies|date=September 2023}}

{{Use dmy dates|date=October 2016}}

{{Use Australian English|date=October 2016}}

Immuron is a biotechnology company based in Melbourne, Australia.{{Cite web|url=http://www.asx.com.au/asx/markets/PriceResults.jsp?method=get&template=F1001&ASXCodes=IMC |title=Anadis |publisher=Australian Stock Exchange |date=2007-06-05 }}{{dead link|date=July 2017 |bot=InternetArchiveBot |fix-attempted=yes }} In 2008, the company changed its name to Immuron Limited,{{Cite web |title=About Us |url=https://www.immuron.com.au/about-us/ |access-date=2022-05-07 |website=immuron1 |language=en}} having previously operated as Anadis Limited.{{Cite web |title=Immuron Limited - ABN, ACN, Business names, Former names |url=https://www.aubiz.net/company/immuron-limited-063114045/ |access-date=2022-05-07 |website=www.aubiz.net}}{{Cite web |title=IMMURON LIMITED - Australia Company |url=https://australia-corp.com/co/immuron-limited |access-date=2022-05-07 |website=australia-corp.com}}

Immuron is focused on antigen-primed and dairy-derived health products. Its proprietary technologies allow for rapid development of polyclonal antibody and other proteins-based solutions for a range of diseases.{{Citation needed|date=March 2011}}. The company specialises in nutraceutical, pharmaceutical and therapeutic technology products for conditions such as oral and GI mucositis, avian influenza, E. coli travellers' diarrhoea (TD) and Anthrax containment.

In 2005, Anadis signed an agreement with Quebec's Baralex Inc. and Valeo Pharma Inc. for the distribution of Travelan, a product made by Anadis for the Canadian market.{{Cite web|url=http://www.asiapacific.ca/news/valeo-pharma-baralex-sign-distribution-agreement-australias-|title=Valeo Pharma, Baralex Sign Distribution Agreement with Australia's Anadis Ltd.|last=Canada|first=Asia Pacific Foundation of|website=Asia Pacific Foundation of Canada|access-date=2017-09-18}}